Australian clinical-stage company Immutep has announced positive data from the INSIGHT-003 trial evaluating its eftilagimod alpha in combination with MSD's KEYTRUDA (pembrolizumab) and chemotherapy for first-line treatment of metastatic non-squamous non-small cell lung cancer. …
Australian company says 'Efti' INSIGHT-003 lung cancer trial reveals positive survival data
November 14, 2024 Latest NewsBioPharma
Latest Video
New Stories
-
The need to honour a strong history while ensuring the future is guided by the 'good guys'
November 17, 2025 - - Latest News -
BMS Australia team cycles across Japan, raising nearly $20,000 for Bowel Cancer Australia
November 17, 2025 - - Latest News -
Syntara secures positive European opinion for orphan designation of amsulostat in myelofibrosis
November 17, 2025 - - Australian Biotech -
Mesoblast appoints Chief Financial Officer as it evolves into fully integrated commercial organisation
November 17, 2025 - - Australian Biotech -
Argent BioPharma secures significant financing facility to support strategic expansion
November 17, 2025 - - Australian Biotech -
Race Oncology launches new clinical programs in AML and lung cancer
November 17, 2025 - - Australian Biotech -
Noxopharm begins daily dosing in second phase of HERACLES trial
November 17, 2025 - - Australian Biotech